Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.
Jin Qian, PhD
Advertisement
Articles by Jin Qian, PhD
Advertisement
Latest Updated Articles
Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.Published: May 13th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5